

OCTOBER 9, 2024

Myriad
genetics

Investor Day 2024



Forward-looking statements and Non-GAAP financial measures

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

Some of the information presented here today contains projections or other forward-looking statements regarding future events, the future financial performance of the Company, or the Company's expectations, intentions, beliefs or strategies regarding the future. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.

Today's agenda

Paul J. Diaz
PRESIDENT AND CHIEF EXECUTIVE OFFICER



Well-positioned to drive long-term growth, innovation and profitability
Focus on quality, commercial execution and innovation

Sam Raha
CHIEF OPERATING OFFICER



Strengthening capabilities, leveraging operational excellence to drive profitable growth
Leveraging scale, driving productivity and innovation, Labs of the Future program, and digital strategy

Mark Verratti
CHIEF COMMERCIAL OFFICER



Addressing large underpenetrated markets with differentiated products and services
Expanding genetic testing in markets affecting millions of lives

Executing to win
Expanding commercial sales and marketing capabilities to increase access to genetic testing and drive growth

Dale Muzzey, Ph.D.
CHIEF SCIENTIFIC OFFICER



Enhancing existing products & innovating in new areas
Advancing clinical utility to reach more patients and developing new products to pursue opportunities in precision medicine

Scott Leffler
CHIEF FINANCIAL OFFICER



Delivering financial performance & shareholder value
Focus on long-term growth and profitability

Paul J. Diaz

President and
Chief Executive Officer

Well positioned to drive long-term
growth, innovation and profitability

Revealing the power of genetic science – for everyone



Mission

We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.



Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.



Myriad Genetics at-a-glance



A leader in genetic testing

Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing



30+ years of scientific and commercial achievements

1,000+ scientific publications and counting



51,000+

active ordering
healthcare providers¹

72

net promoter score²

~2,700

employees³



13% annual revenue growth through Q2 '24

Commercial execution driving volume growth; price stability



Market-leading gross margins; healthy balance sheet



Innovation in '25 and beyond

Investing in core products and launch of multiple differentiated tests in prenatal and oncology through 2026

1. Total number of providers having placed an order in last 3 months, as of June 2024
2. As of July 2024
3. As of December 31, 2023

Market dynamics in healthcare are creating new opportunities



Healthcare is evolving to be more **patient-centered and value-based**



Genomic insights and precision medicine can play an important role in advancing care, improving access and reducing costs



Rapid acceleration of automation and advanced sequencing platforms giving rise to scalable models to engage/sell/manage operations



Scientific advances in new therapies fueling demand for supporting diagnostics and more therapy selection products



Ongoing market disruption in our sector presents market share gain opportunities for companies best positioned to win

Our diversified portfolio offering



Oncology

Clarifying cancer treatment with genetic insights and companion tests that are designed to work with corresponding treatments.



Women's Health

A leader in health and wellness with best-in-class genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.



Pharmacogenomics

Using genetic insights to help healthcare providers understand how genetic alterations impact patient response to antidepressants and other drugs.



Large, fragmented and actionable markets

	Oncology			Hereditary Risk	Women's Health	PGx	
	MRD	TUMOR PROFILING	HRD ²	AFFECTED HCT + GERMLINE	UNAFFECTED HCT	PRENATAL	PHARMACO-GENOMICS
Actionable Market Opp. ¹	\$20B+	\$3.8B	\$0.3B	\$1.7B	\$4.6B	\$2.6B	\$2B
Market Growth Rate (2024 Est)	15%+	10 - 15%	5 - 10%	4 - 5%	8 - 10%	3%	13%
Myriad Products	<i>Precise MRD (pipeline)</i>	Precise Tumor <i>Precise Liquid (pipeline)</i> Polaris	MyChoice CDx	MyRisk BRAC CDx	MyRisk with RiskScore BRAC CDx	Foresight Prequel <i>FirstGene (pipeline)</i>	GeneSight

>\$33B

Of actionable market opportunity

Myriad addressing or expanding into

Faster Growth

markets with a number of segments growing double digits annually

Top 3 Position

in 4 out of 7 active product categories

Clear strategy for long-term value creation and strong execution fueling current revenue growth



Oncology +



BioPharma

Investing in increasing content, breadth of offering & paired testing

- ✓ Expanding MyRisk[®] gene panel and clinical evidence
- ✓ Increasing demand for pairing Precise Tumor[®] & Precise[®] Liquid (*pipeline*) with MyRisk (and Prolaris + MyRisk)
- ✓ Expanding myChoice to Prostate and Breast for U.S. and Japan

Advancing unique Precise[®] MRD program

- ✓ Accelerating clinical studies, and publications
- ✓ Strengthened IP portfolio securing freedom to operate
- ✓ Opportunity to leverage IP for licensing revenues

Compelling value proposition for BioPharma

- ✓ Fuels evidence generation
- ✓ Potential source of profitable revenue growth

+15%

MyRisk Oncology

Revenue growth¹

Myriad genetics[®]

1: LTM as of June 30, 2024

Positioned to increase market share & profitability

Leading clinical value



Women's Health

Gaining market share through on-going market disruption

- ✓ Displacement from exiting competitors
- ✓ Expanding to new channels: integrate delivery networks, hospital systems and out-patient provider groups

Enhancing current products and expand utility

- ✓ Foresight® increased adoption and reimbursement with expected expansion in guidelines
- ✓ Prequel® industry-leading early (8 week) gestational age indication and 22q
- ✓ MyRisk® with RiskScore® extending leadership in HCT with new content

Novel multi-screen prenatal panel

- ✓ FirstGene™ combined carrier screen + NIPS with a single maternal blood draw (pipeline)

+26%

Women's
Health

Revenue growth¹

Myriad genetics®

1: LTM as of June 30, 2024

©2024 Myriad Genetics, Inc.

11

A leader positioned for continued growth



Pharmacogenomics

Expanding volume

- ✓ Through large and untapped primary care channel
- ✓ With increasing efficiency in our targeted digital outreach and demand-generating marketing programs

Expanding coverage and improving average revenue per test

- ✓ Growing momentum around state biomarker legislation
- ✓ Ongoing clinical evidence generation

Improving medication administration

- ✓ Exploring new indications

+16%

GeneSight
Revenue growth¹

Myriad genetics®

1: LTM as of June 30, 2024

Cornerstones of our future growth and innovation

4 Strategic Pillars

Science and innovation



Elevated customer experience and commercial execution



Myriad
genetics®




Technology enabled operations



Scalable commercial, lab operations and administrative support services

Top 5 Provider Test Requirements


Germline Providers (ranked by importance)



Source: proprietary report from third party consulting firm, 2023.

Journey to revitalize Myriad and build the foundation for future growth

Executing to our strategy to deliver high clinical value for patients and providers with a sustainable business model



First look at third quarter revenue; Reaffirm 2024 revenue guidance



Q3 revenue

Preliminary total revenue of **\$210M - \$212M**, despite the divestiture of EndoPredict business in the EU



Reaffirm 2024 financial guidance

Total revenue: **\$835 - \$845 million**
Adjusted EPS: **\$0.08 - \$0.12**

Sam Raha

Chief Operating Officer

Strengthening capabilities,
leveraging operational excellence
to drive profitable growth

Rebuilding the Myriad Genetics brand among clinicians

A deliberate strategy to better meet the needs of patients and providers


WHAT MATTERS

FOCUSED INVESTMENT & EFFORTS TO IMPROVE

- 01 **Clinical Utility** ▶ Investment in clinical evidence, expanded panels
- 02 **Comprehensive Test Offerings** ▶ Expanded Oncology portfolio
- 03 **Turn-Around-Time** ▶ Improved Lab Operations & Customer Service
- 04 **Ease-of-Use** ▶ Significant investments made to improve customer experience
- 05 **Affordable** ▶ Expanded coverage, increased cost transparency
- 06 **Scientific Contribution** ▶ Industry-leading contributions to ClinVar
▶ Myriad Collaborative Data Registry
- 07 **Trustworthy Lab** ▶ Expert support for large health systems
▶ Expanded KOL & Genetic Counselor engagement

Report an improved opinion of Myriad YoY

+19%
Increase YOY



Setting a strong foundation for accelerating growth & profitability

Investing in core capabilities across the enterprise focused on improving experience and operational excellence at scale



Focused, insight-driven and user-centric product innovation with clear path to reimbursement



End-to-end automation, process improvements and policy changes to reduce friction for patients, providers and payors



Reducing operational costs and increasing efficiency and scalability across multiple organizations

*Across key operations and sales functions, 2021 - 2024

Significant investment in state-of-the-art labs, standards-based technology infrastructure, advanced AI and automation resulting in productivity gains*




+28% customer service

+18% lab operations


Advancing digital architecture end-to-end

Delivering differentiated customer experience, higher productivity and improved reimbursement



Removing friction and enhancing our support of patients and providers


Focusing our efforts where it matters most across the customer journey



Deploying industry-leading EMR solutions in all channels

Streamlining workflows, expanding access and driving added volume

New EMR-Integrated Provider Sites



¹ Year-to date as of September 2024
² Target total new sites to be integrated in 2024

Oncology Focus

+

2,000+ cancer care clinicians nationwide

- Full suite of oncology products
- Detailed variant data

Ongoing Investment

MYRID EMR NOW	MYRIAD EMR NEXT
Strategic EMR vendors for all channels	Expand availability of full portfolio & platforms for oncology

* In negotiations at present

Building for growth with the Labs of the Future program

Objectives

To drive innovation and operational excellence at scale and deliver high quality results with shortened turnaround times and lower COGS per test

2024 highlights

- Regulatory permitting / approvals
- Oncology volume ramping in new Salt Lake City lab
- Prenatal volume ramping in new S San Francisco lab
- Intermountain Precision Genomics integration
- Transitions to be completed in 2025

Impact

- ✓ **>40%** reduction in annual lease costs expected*
- ✓ **>3M** annual sample processing capacity

Myriad Precise Tumor

Strategic acquisition and integration



Intermountain Health Precision Genomics
ST. GEORGE UTAH → SALT LAKE CITY

Advanced R&D

Incubate / advance new technologies

65k

square feet



Walter Gilbert Innovation Center
SOUTH SAN FRANCISCO

Scaled Operations

Process high volume products

235k

square feet



Myriad Genetics HQ and Central Lab Operations
SALT LAKE CITY

Leveraging operational excellence at scale

Improving lab capabilities end-to-end with advanced automation, delivering richer insights for patients



Systematic approach on delivering:



High quality test results



Faster turn-around times



Improved costs

Evaluating new advanced diagnostic technologies

Driving scale, decreased costs, and enabling impactful innovation



Key criteria for development and deployment:



Drive Scale:

Enhance our ability to interrogate more of the human genome in short time at ever increasing test volumes



Lower total cost per data point:

Reagent costs are only a portion of our total cost per test



Enable impactful innovation:

Technology that allows us to push the boundaries of our mission

illumina®



Artificial Intelligence and our emerging capability



Foundations of Science

Myriad's tradition of innovation powered by rigorous stats and machine learning

EXAMPLES

- Unique insights in core products
- Critical element of new differentiated assay development



Workforce Productivity

Increase workforce leverage by expanding Microsoft Copilot

EXAMPLES

- Content creation
- AI-enhanced robotics automation



Automation for Growth

Efficiently scale to meet demand by removing tedious manual processes

EXAMPLES

- AI-driven patient identification
- AI-enhanced eligibility, prior-auth and exception management expected to increase average revenue per test



Leveraging partnerships with AI expertise: AWS, DNAnexus, Epic, Microsoft, Salesforce, Xifin

Leveraging AI-powered workflows where they can have the highest impact



From identifying unaffected patients in Women's Health who qualify for MyRisk to increasing cash collections, AI is a tool to support our growth and improve the bottom line



Improving patient education and Customer Service to increase testing

- Myriad AI-driven patient in-take platform to gather family history and risk factors
- Integrated with EMR to speed ordering



Reducing No-Pay rates

- AI-assisted prior-authorization submission
- AI data extraction to improve billing accuracy

Patient Identification

AI-powered Myriad MyGene History™



Reimbursement

Automated revenue cycle management
Advanced analytics platform



Strengthening core capabilities and leveraging operational excellence to drive profitable growth



Fueling top line growth based on relentless focus on customer-centric innovation and experience

High clinical value through customer-driven product innovation

Removing friction through advanced automation and digital workflows



Supporting margin expansion with enhanced capabilities and rigorous cost management

Leveraging the power of AI to maximize engagement and revenue operations

Lowering cost-of-goods-sold (COGS) with a strategic approach to managing key suppliers



Increasing operational efficiency by leveraging process optimization and new technologies

Automating end-to-end to scale operations, speed innovation, and increase agility

Leveraging technology partnerships to strengthen offerings and reduce costs

Mark Verratti

Chief Commercial Officer

Addressing large underpenetrated markets
with differentiated products and services

Executing to win

Key market trends forcing diagnostic companies to evolve

Healthcare practices continue to consolidate with the rise of outpatient care

As providers falter, trust and lab reputation have become key selection criteria

Providers increasingly looking for a portfolio of products and workflow solutions


~78% of US physicians are employed by hospitals, health systems, and other corporate entities (up from ~26% from 2012)²

Trust-worthy lab I am proud to work with is #2 most important driver of lab choice

Comprehensive product offering is a top attribute for increasingly overwhelmed clinicians




The Myriad Enterprise brand is strong, performing above competitor average in “Likelihood to Recommend” and “Positive Feeling About the Company”.¹




¹Myriad Brand Equity Study 2024;

²Physicians Advocacy Institute Accessed 9/30/24 <https://www.physiciansadvocacyinstitute.org/Portals/0/assets/docs/PAI-Research/PAI-Avalere%20Physician%20Employment%20Trends%20Study%202019-2023%20Final.pdf?ver=uGHF46u1GSeZgYXMKFyYvw%3d%3d>,

A strong, scalable commercial team unified in a singular goal



COMMERCIAL TEAM MEMBERS



Our commitment to patients and the providers that treat them comes from a

>650
person team*


Dedicated, highly efficient Commercial organization delivering

+68%

more revenue per Commercial team member since 2021*

*as of September 2024

Seeding growth driven by strength of the complete portfolio





Pharmacogenomics

Goal: Drive double-digit revenue where we have strategic advantage in the primary care market

Opportunity

\$2B

market growing at **13% CAGR**

>\$150M

TTM revenue¹ driven largely by **primary care clinicians**

Our focus



Expand coverage with growing state biomarker laws



Refine targeting to maximize opportunity for reimbursement



Expand indications to address other medication administration issues



Continue evidence generation to prove clinical value

Key clinical question

“Are there drugs for treating major depressive disorder where my genetics may mean that standard dosing recommendations are inappropriate for me?”





¹As of June 30, 2024

Women's Health

Goal: increase access to genetic insights for patients receiving care across women's health channels

Who we serve

 Women of all ancestries, receiving care across their healthcare journey

 And the OB/GYN and primary care clinicians who care for them across independent practices, imaging centers and large health systems

Our focus



Expanding access and equity in differentiated genetic diagnostic insights



With a portfolio of women's health tests spanning prenatal planning to cancer risk



Affordable products that meet guidelines

28%¹

YoY revenue growth

Key clinical questions

Cancer risk

"Based on hereditary genetic information, what is my risk of developing a first cancer?"

Carrier risk

"Are my reproductive partner & I asymptomatic carriers of a severe recessive disease?"

Fetal risk

"Does my developing fetus have a chromosomal abnormality that could impact its health & viability?"

Accelerating profitable revenue growth in prenatal care

Prequel[®]
Prenatal Screen

Market Size (US only)
~\$1.7B

Expected Market Growth
High single digit

Market Penetration
53%

Myriad Papers Published
11

Foresight[®]
Carrier Screen

Market Size (US only)
~\$0.9B

Expected Market Growth
Low single digit

Market Penetration
45%

Myriad Papers Published
25

Product attributes

Foresight Carrier Screening

- Highest published at-risk couple detection rate for serious conditions

Prequel NIP Screening

- Unique AMPLIFY technology delivers industry-lowest first-time screening failure rate²

Prenatal enhancements

Foresight Universal Plus


- Gene expansion to meet expected new guidelines should drive increased adoption and reimbursement

Prequel Early Gestational Age

- First-time results available to >99.9% of patients at 8 weeks¹
- Adding 22q with expanded guidelines

Prenatal revenue growth **+37%**³

Q2 '24 LTM Revenue Growth (YOY)



¹ Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genet Med 23, 443–450 (2021).

² Hancock et al. 2020. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020 Sep;56(3):422-430.

³ Calculated at the increase from the 12 months ended June 30, 2024, as compared to the 12 months ended June 30, 2023. For detail of our quarterly prenatal revenue please see our current and prior earnings releases.

Increasing hereditary cancer risk testing for unaffected women

Market Size
(US only)
~\$4.6B

Expected Market Growth
8 - 10%

Market Penetration
>9%

Myriad Papers Published
98



Product attributes

MyRisk

- Gold standard for hereditary cancer testing
- Analyzes risk of developing 11 types of hereditary cancer

RiskScore

- Polygenic test for women of all ancestries
- More accurately estimates woman's lifetime risk of developing breast cancer




MyRisk and RiskScore enhancements

- MyRisk Gene Panel Expansion
- RiskScore increased content
- Medical Management Tool enhancements
- MyGene History integration into key EMRs



MyRisk WH revenue growth



* Calculated at the increase from the 12 months ended June 30, 2024, as compared to the 12 months ended June 30, 2023.

Our commitment to uncovering breast cancer risk

30 years and counting



Over a decade of providing patients with hereditary cancer risk

11 years since the launch of MyRisk



Comprehensive risk assessment to provide 5-year and lifetime cancer risk

Density + Risk Model + Genetics to provide 5-year Breast Cancer risk and lifetime hereditary risk of 11 different cancers



Impactful short and long-term medical management

50%+ of all patients who take a MyRisk test get a medical management change with assistance by 50+ live genetic counselors¹




¹ Myriad Internal Data based on OBGYN & Primary Care Setting

Improving patient care through breast cancer risk assessment and genetic testing

American College of Radiology and Society of Breast Imaging have called for all women 25 years of age and above to have their risk assessment completed³



1 Patient identification & education



Text-based risk assessments completed by over 12,000 patients (from four pilot sites, 4/23 – 10/24)

2 Risk stratification



Average-risk patient

Proceed with standard screening (e.g., annual mammo)



Elevated-risk patient

Supplemental screenings (e.g., MRI / ABUS -> TC >20%)



High-risk patient

Recommend tailored screening & care plan

53%

of patients tested are candidates for enhanced screening¹⁻³

3 Modified medical management



Increased surveillance

(e.g., annual MRI / US)



Risk-reducing interventions

(e.g., medication + surgical options)



Family considerations

(e.g., screening / genetic testing)

1. DeFrancesco, et al. Obstetrics & Gynecology, Nov 2018 2. Hughes et al. NCBC Abstract (2023 Meeting). 3. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023;20(9):902-914. doi:10.1016/j.jacr.2023.04.002

Goal: Bring the “clarity” of genomics to more patients

Who we serve



Community Oncologist with a focus on treating high-incidence cancer in the community

Our Focus



Delivering diagnostic insights with clear clinical utility



with a portfolio of oncology offerings with utility across the patient journey



and products with a path to guidelines and imminent reimbursement

11%¹ YoY
MyRisk Affected
Revenue growth

Key clinical questions

CANCER RISK

“Based on hereditary genetic information, what is my risk of developing a subsequent cancer?”

CANCER TREATMENT

*“Does the genome of my solid tumor tissue have variants that mean my doctor should treat me with particular therapies?
Clinical trials where I’m eligible to participate?”*

Understanding the Community Oncologist

“

Generally, there has been a slow move towards precision medicine. There are real obstacles in terms of matching diagnoses to therapies. To understand which techniques are appropriate for prime time; which biomarkers might be most relevant and actionable to bring into the practice.”

*Medical Director
Community Hospital System*

Myriad genetics®

83%

Of all first-time patients **diagnosed** in the community setting


~50%

Of all oncology patients **receive care** in the community

Source: JAMA Network Open. 2021;4(7):e2115675.
doi:10.1001/jamanetworkopen.2021.15675



The complete Myriad Oncology offer



Accelerating hereditary cancer revenue growth in Oncology

Market Size
(US only)

~\$1.7B

Expected Market Growth

Low single digits

Market Penetration

>70%

Total Myriad Papers Published

98



Product attributes

- The gold standard for hereditary cancer testing
- With best-in-class reporting and medical management guidance




MyRisk enhancements

- Medical Management Tool
- STAT ordering
- MyGeneHistory integration into key EMRs
- Gene panel expansion in 2025E



MyRisk revenue growth **+15%***



* Calculated at the increase from the 12 months ended June 30, 2024, as compared to the 12 months ended June 30, 2023.

Resetting the opportunity in Tumor Profiling and Therapy Selection

Prolaris® <small>Prostate Cancer Prognostic Test</small>	Market Size (US only)	Expected Market Growth	Market Penetration	Myriad Papers Published
Precise™ Tumor <small>Molecular Profile Test</small>	~\$2.2B	10 - 15%	43%	26 Prolaris 100 Precise Tumor
MyChoice® CDx <small>Myriad HRD Companion Diagnostic Test</small>	Market Size (US only)	Expected Market Growth	Market Penetration	Myriad Papers Published
	\$0.3B	5 - 10%	34%¹	40




Product attributes

- **Prolaris:** Leading prostate cancer prognostic to address disease progression
- **Precise Tumor:** Comprehensive genomic panel for therapy identification
- **MyChoice:** FDA approved to determine PARPi eligibility based on genetic mutations



Tumor Profiling enhancements

- **Prolaris:** 10-year risk improvements and lymph node guidance
- **Precise Tumor:** Illumina secured CDX indication on TSO 500 kit
- **MyChoice:** Japan studies underway to expand indications to breast, prostate



Accelerating revenue in our core with increasing commercial effectiveness & an increasingly competitive portfolio

Highly-engaged, skilled team maximizing revenue opportunities

- Leveraging a seasoned sales force to expand our channel footprint
- Realize the full value of the complete portfolio

Armed with a portfolio of products with high clinical utility

- Core products that cater to growing, underpenetrating markets
- Complementary test offerings for comprehensive, high-quality care

Improving efficiency & removing friction for our customers

- Product-design carefully informed by customers and channels that we serve
- EMR integrations that enable clinician workflows and support the delivery of care

Dale Muzzey Ph.D.

Chief Scientific Officer

Enhancing existing products
& innovating in new areas

Guiding light for R&D at Myriad

Patients



Observations

- Often not:
- Treated by specialists
 - Receiving guideline-recommended genetic insights
 - Of Northern-European descent

Strategy

Provide exemplary, accessible, equitable genetic offerings that enable all patients to receive testing that meets or exceeds guidelines.

Providers



- Often:
- See >20 patients per day
 - Need to administer multiple genetic tests
 - Not experts in genetics

Aggregate and simplify the delivery of genetic insights that empower action

INGENUITY



PRACTICALITY



UTILITY



SIMPLICITY



ACCESSIBILITY



EQUITY

Active expansion of high-quality testing pipeline, addressing real-world community needs

Precise Oncology Solutions

Precise Tumor[®] Launched

Robust tumor profiling & therapy selection

Pan-cancer comprehensive genomic profiling test; may serve as first-line offering

Precise[®] Liquid Target: Q1'26 Commercial Launch

Robust tumor profiling & therapy selection

Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

Precise[®] MRD RUO Launched

Molecular residual disease monitoring

Monitoring test based on whole genome sequencing; detect recurrence earlier and help guide treatment decisions

Women's Health

Foresight[®] Launched

Expanded carrier screen: Universal Plus

Pioneering expanded NGS carrier screen finds pathogenic variants underlying recessive disease with increase guidelines to improve adoption, payor coverage

Prequel[®] Q1'25 Launch

at Earlier Gestational Age

GA is a key driver of when fetal aneuploidy testing can be reliably performed. Prequel with AMPLIFY enables testing at 8-weeks GA vs. industry at 10-weeks

FirstGene[™] H1'25 Pre-Launch

Multiple prenatal screening

Integrated assay for NIPS + carrier screen + fetal recessive status + feto-maternal blood compatibility

Expanding market opportunities with the recent launches

Foresight Universal Plus

A more comprehensive carrier screening panel



Foresight Universal Plus

- Expansion of guidelines should help drive adoption and payer coverage
- Platform upgrade designed to harmonize workflow and cost advantages
- Panel expansion will support average revenue per test increase with minimal additional cost per test

Prequel at Earlier Gestational Age

Prequel with GA at 8-weeks vs. most of industry at 10-weeks



Prequel at Earlier Gestational Age

- Testing at 8-weeks GA facilitates patient/provider clinical workflow and allows more time to plan for diagnostic testing.
- Prequel's unique AMPLIFY technology that boosts fetal signal enables earlier GA, when fetal signal is typically lower


Transformative prenatal screen running multiple tests at once

Current CHALLENGES with prenatal genetic screening

Providers don't have enough time to talk about genetics



Only **50%** utilization of carrier screening




Only **30%** of fathers get screened when mother is a carrier

Low gross margins on **NIPS** and **ECS**



Our SOLUTION

FirstGene™
Multiple Prenatal Screen



- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone

Exemplary performance of FirstGene for fetal status nearing that of established prenatal screening

598-sample Validation Study

		SENSITIVITY	SPECIFICITY	PPV	NPV	
	Non-invasive Prenatal Screening	Aneuploidy (trisomies, SCAs, μ deletions)	100%	99.8%	98%	100%
	Carrier Screening	Recessive variants in pregnant person	99.9%	99.9%	99.9%	99.9%
NEW!	Fetal recessive status	Recessive variants in fetus	99.2%	99.8%	99.3%	99.8%
NEW!	Blood compatibility	Rhesus D Antigen	100%	100%	100%	100%

Validation studies update

- ✔ **4** analytical validation (AV) posters presented at NSGC
- ✔ Manuscript submitted for **peer review**
- ✔ **NYS validation** submitted
- ✔ **H1 '25 pre-launch**
study initiation to gather Clinical Validity and Clinical Utility data on >4,000 pregnancies to begin

Precise MRD: Partnerships with world-leading collaborators






We anticipate the **MRD test from Myriad will be more sensitive and specific than many other ctDNA offerings** for monitoring the response and, therefore, may more accurately identify the patients who will or will not benefit from certain therapies. Importantly, some of these patients may go undetected on a less-sensitive MRD test.”

Dr. Pedram Razavi

Director of Liquid Biopsy & Genomics
Memorial Sloan Kettering Cancer Center

Precise MRD: Differentiation built upon existing competencies




- ▲ Higher sensitivity: detection at 10x lower tumor levels
- ▲ 100x more of the genome explored
- ▲ Over 60x more targeted sites
- ▲ Earlier detection of recurrence

*3 patents issued


Whole Genome-based Precise MRD is ultrasensitive with low background noise

Myriad Precise MRD vs others

	Limit of Detection (ctDNA per million cfDNA)
Myriad Precise MRD	<5
Laboratory A ¹	3.45
Laboratory B ²	100
Laboratory C ³	80
Laboratory D ⁴	100
Laboratory E ⁵	3000



When sensitivity matters



Advancing our innovative Molecular Residual Disease (MRD) program on multiple fronts

Strengthening intellectual property portfolio

- Announced adding three patents to the portfolio family in 2024 (filing dates in 2016)
- Entered a cross-license agreement with Personalis related to patent estates covering tumor-informed approaches to detect MRD (July 2024)

Established research collaborations with prestigious institutions across multiple disease indications

- Top oncology research institutions such as MD Anderson, Memorial Sloan Kettering and National Cancer Center Hospital East in Japan
- Indications include breast, ovarian, prostate, endometrial, renal, and bladder cancers













Expanding number of prospective and retrospective studies and publications through 2026

In advanced negotiations to form strategic alliance with leading national cancer center

Institution looking to utilize a highly sensitive MRD assay for trials across several indications



Myriad Precise MRD study overview

Indication	Study Types	Total Patients	Statuses
Breast (x8)	  	>1700	Enrolling, running samples, proposal
Renal (x5)	 	>400	Enrolling, running samples
Ovarian (x3)	 	>350	Enrolling, running samples
Multicancer		~1,100	Enrolling, running samples
Other (x4)	   	~600	Enrolling, running samples, proposal

-  Myriad Prospective
-  Investigator-Initiated Prospective
-  Retrospective Collaboration
-  Prospective Interventional



>4,000 patients

>30,000 timepoints

7+ indications

Precise MRD: Key milestones

2024

Offer Precise-MRD for research use only (RUO)

Continue to strengthen IP portfolio

Partner on retrospective clinical validation

Work with leading cancer centers eager to use HD-MRD

Begin prospective clinical validity studies

Three institutions onboarded; patient enrollment underway

Scale laboratory operations

Low-touch, high-capacity, and high-quality with low COGS

2025+

Offer Precise-MRD for biopharma partners

Submit clinical validity studies

Retrospective longitudinal cohorts; one per indication

Submit for reimbursement to CMS

Show non-inferiority to currently covered tumor-informed tests

Commence clinical-utility study

Focus on provider utilization and patient outcomes


Continue scaling laboratory operations

Low-touch, high-capacity, and high-quality with low COGS

2026 Target commercial launch with Breast as first indication

Establishing the evidence: A robust study and publication pipeline

STUDIES AND PUBLICATIONS



*(accepted, submitted, or in-prep)

FirstGene™
Multiple Prenatal Screen

Analytical validation study submitted, 4 abstracts presented at NSGC

Prequel®
Prenatal Screen

Published study¹ showed exceptional positive predictive value for 22q11.2 microdeletion: 22/22 confirmed positive

MyRisk®
Hereditary Cancer Test

MyRisk with RiskScore: podiums at ASCO '24 and SABCS '24, Clinical Utility study submitted

Precise™ MRD
Minimal Residual Disease Monitoring

More than 15 studies underway across breast cancer and other indications, abstract(s) submitted to ASCO-GU

1. <https://pubmed.ncbi.nlm.nih.gov/38622914/>

Creating an environment for improving and advancing cancer care

Myriad Collaborative Research Registry

The **Myriad Collaborative Research Registry** advances patient care by combining structured clinical data with genetic and genomic results

Researchers utilizing the Registry have already begun to generate abstracts presented at medical conferences in 2024, including at

ASCO[®] AMERICAN SOCIETY OF
CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

The registry includes the following de-identified data:



>1.1 million patients included



Several represented cancer types



Gene expression, tumor, and germline testing results



Scientifically valid and regulatory compliant

Once granted access and trained, clinicians and researchers can use the research portal for immediate exploration.


Queries and analyses conducted can foster further research opportunities.

Scott Leffler

Chief Financial Officer

Delivering financial performance
& shareholder value

Focus on the customer experience and commercial execution with a diversified portfolio driving double-digit revenue growth



1. Last twelve months as of June 30, 2024
 2. Last twelve months as of the quarter end indicated



LTM¹ revenue growth (YOY) across breadth of product offerings:

- GeneSight: 16%
- Hereditary cancer: 15%
- ProLaris: 10%
- Prenatal: 37%



Revenue growth driven by:


- Commercial execution across current provider base; winning new business
- Improving provider perceptions
- Operational execution (e.g. lower turnaround times)
- Shifts in competitive landscape across select markets

Q2 '24 spotlight on US strength and international restructuring


US / ROW total revenue and growth rates

All figures in millions, except growth rates

US total revenue:



ROW total revenue:



US highlights:

25% Hereditary cancer revenue growth YOY

25% Prenatal revenue growth YOY

22% Pharmacogenomics revenue growth YOY

ROW highlights:

HCT revenue declined due to Japanese Yen depreciation

Transitory issues - EU reorganization

Continue to see opportunities for focused profitable growth in Japan

Ongoing activities supporting sustainable pricing environment going forward



Revenue cycle process improvements

AI-enhanced insights;
Accelerate EMR integrations

Deploy Unified Order Management to reduce friction



Invested in revenue cycle and pre-authorization team

Added headcount and continue to integrate Robotic Process Automation (RPA) to off-load repetitive tasks



Ongoing payor and 3rd party engagement

State biomarker legislation leading to new coverage opportunities

Increasing engagement with Lab Benefit Managers (LBM)

Industry developments



Favorable positive pricing environment

Clinical society guideline expansions


Increased industry consolidation activity

Increased public focus on payor behavior


2Q24 year-to-date* average revenue per test has increased 4% YOY reflecting expanded payer coverage and momentum of RCM initiatives

A deeper dive into average revenue per test trends

Hereditary Cancer Test



GeneSight Test



Drivers and recent highlights



Guidelines and payor coverage

- American Society of Clinical Oncology expanded guidelines on germline testing (2024)
- Blue Shield of California and Centene-Peach State (PGx coverage, 2024)
- UnitedHealthcare (2024)



Payor contract wins

- UnitedHealthcare expanded coverage of MyRisk and coverage of Prolaris (2024)
- Cigna recently instituted coverage of ForeSight
- 2025 Clinical Lab Fee Schedule (CLFS) preliminary rate for hereditary cancer testing INCREASED over prior rate (September 2024)




Revenue Cycle Management

- Investments in technology (e.g. optical character recognition) and pre-authorization team

Financial progression by quarter (2023 – Q2 '24)

All figures in millions, except per share amounts and percentages



*GAAP to non-GAAP reconciliations can be found in the appendix.

Reaffirm 2024 revenue and non-GAAP financial guidance


All figures in millions, except per share amounts

	2024 FINANCIAL GUIDANCE	2024 COMMENTS
Total revenue	\$835 - \$845	2024 annual growth between 11% - 12% over 2023.
Gross margin %	70.0% - 70.5%	GM expected to fluctuate in any quarter given seasonality.
Adjusted operating expenses*	\$575 - \$585	2024 annual growth between 6% - 8% over 2023.
Adjusted EBITDA*	\$25 - \$35	2024 adjusted EBITDA growth of \$36 to \$46 million over 2023.
Adjusted EPS*	\$0.08 - \$0.12	

Assumes currency rates as of October 9, 2024

*The company does not forecast GAAP operating expenses, earnings before interest, tax, depreciation, or amortization (EBITDA), and earnings per share because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation for more information about the use of non-GAAP financial measures.

Accelerating growth expected through prudent investment strategy



2024E revenue reflects the mid-point of current revenue guidance range of between \$835M - \$845M

1 Potential Upside	Expected Long Term CAGR
2 Women's Health	Mid-Teens
3 Pharmacogenomics	Low Teens
4 Hereditary Cancer	Low Double Digits
5 Tumor Profiling	Low Single Digits

Strength of business model expected to drive revenue growth, operating leverage and profitability long-term targets

12%+ revenue growth

Revenue growth expected to benefit from:

- Ongoing commercial execution across focus markets
- Average revenue per test trends remain stable
- Revenue target includes modest contribution from planned new products and no contribution from future M&A

70%+ industry leading gross margins

Gross margins expected to benefit from:

- Ongoing volume growth and product mix
- Lab enhancements and consolidation
- RCM progress
- Opportunity for fixed cost leverage and savings in materials

6-7% CAGR OpEx growth while leveraging SG&A

Ongoing productivity gains across the 580+ sales reps and disciplined spend in growth-focused activities

Double digit Adj. EBITDA margins

Expect Free cash flow (FCF) to track adjusted EBITDA progression

Paul J. Diaz

President and Chief Executive Officer

Closing thoughts

Aspiration



Patient, Provider & Employer of Choice

- Excellence in clinical value
- Removing points of friction
- Ensuring quality in everything we do



Improve Access & Sustainable Growth

- Increase our reach
- Extend digital engagement
- Expand coverage



High-value Innovation

- Patient-centric
- Leading science
- Where we have a right to win



Financial Performance

- Improving average revenue per test
- Focus on gross margin
- Rigorous expense management

Long-Range Financial Targets

12%+ Revenue CAGR

70%+ Gross Margin

Double Digit Adj EBITDA
Margin in 2026

Q&A

Reconciliation of GAAP to Non-GAAP Financial Measures for the twelve months ended December 31, 2022 and 2020

(unaudited data in millions, except per share amounts)

	Year ended December 31,	
	2022	2020 *
Adjusted Net Income (Loss) ⁽¹⁾		
Net Loss Attributable to Myriad Genetics, Inc. Stockholders	\$ (112.0)	\$ (223.6)
Acquisition - amortization of intangible assets	40.9	60.7
Goodwill and long-lived asset impairment charges	16.8	98.4
Equity compensation	37.8	24.4
Transformation initiatives	17.9	18.1
Acquisition-related costs	5.1	—
Legal charges, net of insurance reimbursement	(11.4)	—
Other adjustments	0.7	11.2
Tax impact of non-GAAP adjustments	(20.0)	(38.8)
Adjusted Net Income (Loss)	\$ (24.2)	\$ (49.6)
Weighted average shares outstanding:		
Basic	80.6	74.8
Diluted	80.6	74.8
Adjusted Net Earnings Per Share		
Basic	\$ (0.30)	\$ (0.66)
Diluted	\$ (0.30)	(0.66)

(1) To determine Adjusted Net Earnings Per Share, or adjusted EPS.

*During the 2020 the Company transitioned from a fiscal year ended June 30 to a fiscal year that ended December 31. Consequently, there was a six-month transition period from July 1, 2020, to December 31, 2020.

Reconciliation of GAAP to Non-GAAP Financial Measures for the twelve months ended December 31, 2022 and 2020

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- Goodwill and long-lived asset impairment charges – impairment charges on long-lived assets and goodwill.
- Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- Transformation initiatives – transitory costs such as consulting and professional fees related to transformation initiatives and additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and in South San Francisco, California, while maintaining our current laboratories in those locations.
- Acquisition-related costs - non-recurring costs associated with our acquisition of Gateway Genomics, LLC.
- Legal charges, net of insurance reimbursement – one-time legal expenses, net of insurance reimbursement. For the year ended December 31, 2021, we accrued \$48.0 million for the settlement of the qui tam lawsuit and \$14.0 million for settlement of the Abelli lawsuit.
- Other adjustments – other one-time non-recurring expenses including expenses related to leadership transition, severance and retention agreements, expenses expected to be reimbursed by insurance, and changes in the fair value of contingent consideration related to acquisitions from prior years.
- Tax impact of non-GAAP adjustments – tax expense/(benefit) due to non-GAAP adjustments and differences between stock compensation recorded for book purposes as compared to the allowable tax deductions and the CARES Act legislation.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2024 and 2023

(unaudited data in millions, except percentages)

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Adjusted Gross Margin				
Gross Profit ⁽¹⁾	\$ 147.1	\$ 125.7	\$ 284.8	\$ 247.7
Acquisition - amortization of intangible assets	0.3	0.3	0.6	0.6
Equity compensation	0.6	0.4	0.9	0.7
Transformation initiatives	—	0.2	—	0.2
Other adjustments	0.2	—	0.4	—
Adjusted Gross Profit	\$ 148.2	\$ 126.6	\$ 286.7	\$ 249.2
Adjusted Gross Margin	70.1%	69.0%	69.3%	68.3%

(1) Consists of total revenues less cost of testing revenue from the Condensed Consolidated Statements of Operations.

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Adjusted Operating Expenses				
Operating Expenses ⁽¹⁾	\$ 183.6	\$ 239.4	\$ 349.2	\$ 413.6
Acquisition - amortization of intangible assets	(10.2)	(10.3)	(20.6)	(20.6)
Goodwill and long-lived asset impairment charges	(11.6)	—	(11.6)	—
Equity compensation	(14.0)	(10.8)	(25.6)	(17.9)
Real estate optimization	(2.3)	(3.5)	(3.5)	(11.0)
Transformation initiatives	(2.0)	(2.7)	(4.0)	(6.8)
Legal charges, net of insurance reimbursement	(0.5)	(77.9)	(0.4)	(78.2)
Other adjustments	(2.2)	(0.8)	(3.6)	(1.2)
Adjusted Operating Expenses	\$ 140.8	\$ 133.4	\$ 279.9	\$ 277.9

(1) Consists of research and development expense and selling, general and administrative expense, goodwill and lived-asset impairment charges, and legal settlements from the Condensed Consolidated Statements of Operations.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2024 and 2023

(unaudited data in millions, except per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Adjusted Net Income (Loss) ⁽¹⁾				
Net Loss	\$ (36.7)	\$ (116.1)	\$ (62.7)	\$ (170.8)
Acquisition - amortization of intangible assets	10.4	10.7	21.1	21.3
Goodwill and long-lived asset impairment charges	11.6	—	11.6	—
Equity compensation	14.6	11.1	26.5	18.5
Real estate optimization	2.3	3.5	3.5	11.0
Transformation initiatives	2.1	2.9	4.0	7.0
Legal charges, net of insurance reimbursement	0.6	77.9	0.5	78.2
Other adjustments	2.3	0.8	2.5	1.2
Tax adjustments	(2.7)	2.8	(3.0)	9.8
Adjusted Net Income (Loss)	\$ 4.5	\$ (6.4)	\$ 4.0	\$ (23.8)
Weighted average shares outstanding:				
Basic	90.6	81.7	90.3	81.5
Diluted	91.5	81.7	91.5	81.5
Adjusted Earnings Per Share				
Basic	\$ 0.05	\$ (0.08)	\$ 0.04	\$ (0.29)
Diluted	\$ 0.05	\$ (0.08)	\$ 0.04	\$ (0.29)

(1) To determine Adjusted Earnings (Loss) Per Share, or adjusted EPS.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2024 and 2023

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- Real estate optimization – costs related to real estate initiatives. Prior to the fourth quarter 2023 reporting period, these costs were included in the transformation initiatives category. With respect to the adjusted free cash flow reconciliation, the cash flow effect of real estate optimizations excludes non-cash items such as accelerated depreciation. These costs include the following:
 - For the three months ended June 30, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah, and South Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.
 - For the three months ended June 30, 2023, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah, and South San Francisco, California, while maintaining our current laboratories in those locations.
 - For the six months ended June 30, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah, and South Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities, lease terminations gains, net of lease termination losses, impairment charges and other abandonment costs.
 - For the six months ended June 30, 2023, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah, and South San Francisco, California, while maintaining our current laboratories in those locations, and accelerated depreciation in connection with our decision to cease the use of our former corporate headquarters in Salt Lake City, Utah.
- Transformation initiatives – costs related to transformation initiatives including:
 - For the three and six months ended June 30, 2024, consulting and professional fees.
 - For the three and six months ended June 30, 2023, consulting and professional fees and severance costs related to restructuring.
- Legal charges, net of insurance reimbursement – one-time legal expenses, net of insurance reimbursement. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes cash paid for settlements in the related period.
- Other adjustments – other one-time non-recurring expenses including:
 - For the three months ended June 30, 2024, changes in the fair value of contingent consideration related to acquisitions from prior years, severance, and other consulting costs.
 - For the three months ended June 30, 2023, primarily includes changes in the fair value of contingent consideration related to acquisitions from prior years.
 - For the six months ended June 30, 2024, primarily includes a gain recognized on acquisition, changes in the fair value of contingent consideration related to acquisitions from prior years, the reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity, severance, and costs incurred in connection with executive personnel changes.
 - For the six months ended June 30, 2023, consulting and professional fees related to prior year acquisitions and changes in the fair value of contingent consideration related to acquisitions from prior years.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2024 and 2023

- Depreciation expense - depreciation expense recognized on our fixed assets.
- Goodwill and long-lived asset impairment charges – for the three and six months ended June 30, 2024, primarily the impairment of assets held for sale related to the sale of the EndoPredict business to Eurobio Scientific.
- Contingent consideration payment – for the three months ended June 30, 2024, the payment of contingent consideration related to the previous acquisition of Sividon Diagnostics GmbH.
- Tax adjustments – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States.
 - As of June 30, 2024, a valuation allowance of \$63.3 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance.
 - As of June 30, 2023, a valuation allowance of \$37.2 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance.